Larithro

Clarithromycin, the active ingredient in Larithro, is a macrolide antibiotic presented as an intravenous solution for intravenous use. It treats bacterial infections such as community‑acquired pneumonia, skin and soft‑tissue infections, streptococcal pharyngitis and other severe infections that require rapid systemic therapy in adult patients.

GNH USA supplies Larithro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin is a macrolide antibiotic used to treat bacterial infections in the respiratory and skin‑soft tissue pathways.

- Community‑acquired pneumonia: eradicates typical and atypical pathogens and improves clinical recovery. - Skin and soft tissue infections: reduces bacterial load and promotes healing of cellulitis and abscesses. - Streptococcal pharyngitis: shortens symptom duration and prevents complications. - Severe bacterial infections requiring IV therapy: provides rapid, high‑level systemic exposure for serious infections.

Adverse reactions may occur with clarithromycin therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, sometimes watery. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered or metallic taste. - Headache: mild to moderate intensity. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Hepatic dysfunction: elevated liver enzymes or hepatitis. - QT prolongation and arrhythmias: risk of torsades de pointes. - Severe allergic reactions: anaphylaxis, rash, or angioedema. - Clostridioides difficile infection: severe colitis. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: life‑threatening skin reactions. - Neutropenia or leukopenia: reduced white blood cell counts.

Clinicians should consider several safety measures before initiating clarithromycin IV therapy.

- Assess renal function: adjust therapy in patients with impaired clearance. - Monitor liver enzymes: watch for hepatotoxicity during prolonged use. - Review concomitant QT‑prolonging drugs: avoid additive cardiac risk. - Adjust dose in hepatic impairment: reduce exposure in severe liver disease. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Clarithromycin may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): increase clarithromycin levels and toxicity risk. - QT‑prolonging agents (e.g., erythromycin, cisapride): additive risk of serious arrhythmias. - Statins metabolized by CYP3A4 (e.g., simvastatin): heightened risk of myopathy.

Moderate Interactions (Monitor Closely): - Carbamazepine, phenytoin: may reduce clarithromycin exposure, lowering efficacy. - Warfarin: may increase anticoagulant effect, requiring INR monitoring.